Lords Mark Industries sets ₹1,550 crore FY27 revenue guidance
- Revenue guidance for FY27 set at ₹1,550 crore with EBITDA margin of 20.8%
- MedTech segment expected to contribute ₹825 crore, surpassing renewable energy
- Confirmed order book for dialysis machines exceeds 500 units
- Renewable energy division holds ₹2,000 crore order book through 2030
- Operating cash flow expected to turn positive in FY27 or early FY28

*this image is generated using AI for illustrative purposes only.
Lords Mark Industries Limited provided financial guidance for FY27 during an investor summit on September 10, 2026, projecting consolidated revenue of ₹1,550 crore. The management expects EBITDA margins to reach 20.8% and PAT margins of 12.8% for the fiscal year. This outlook reflects a strategic shift toward higher-margin medical technology products alongside its established renewable energy business.
Financial Outlook and Segment Mix
The company anticipates that the MedTech and IVD segments will contribute approximately ₹825 crore to the total revenue, representing more than half of the top line. Management indicated that MedTech is expected to take the lead over the renewable energy business in terms of revenue contribution in the coming years.
The margin profile varies significantly across business verticals. The IVD and MedTech segment is projected to deliver an EBITDA margin of 23.65% and a PAT margin of 15.46%. In contrast, the renewable energy division is expected to report lower margins, with EBITDA at 17.41% and PAT at 11.8%.
| Segment | Projected Revenue (₹ crore) | EBITDA Margin | PAT Margin |
|---|---|---|---|
| IVD & MedTech | 825 | 23.65% | 15.46% |
| Renewable Energy | ~725 | 17.41% | 11.80% |
| Consolidated | 1,550 | 20.80% | 12.80% |
MedTech Growth Drivers
Lords Mark highlighted several new product launches and partnerships driving the MedTech vertical. The company acquired Renalytics in 2025, which manufactures India's first AI-powered dialysis machine. Management confirmed a confirmed order book of over 500 dialysis machines and plans to operate 50 dialysis centers by March 2027, up from 15 currently operational centers.
Other key developments include:
- Launch of the proprietary sickle cell screening device, aligned with the National Sickle Cell Elimination Mission.
- Exclusive distribution rights for Dozee, a contactless remote patient monitoring system.
- Recent US export orders worth close to $1 million for surgical products.
- Plans to launch two oncology cancer care centers in Vapi and Solapur by June 2027.
Renewable Energy and Order Book
The renewable energy division continues to rely on long-term government contracts. Management disclosed a confirmed order book worth ₹2,000 crore extending through 2030, with expectations of an additional ₹1,000 crore from new contracts. The company remains a key partner for Philips in lighting design, contributing to 26% of Indian railway lighting projects.
What the Numbers Show
The projected revenue mix indicates a significant structural shift in the company's earnings quality. With MedTech contributing roughly 53% of the guided revenue but commanding nearly 6 percentage points higher EBITDA margins than the renewable energy segment, the weighted average profitability is set to expand. This divergence suggests that the growth trajectory in FY27 will be driven less by volume in low-margin infrastructure projects and more by high-margin consumable sales in diagnostics and devices.
Balance Sheet and Liquidity
Addressing investor concerns regarding working capital, management clarified that consolidated receivables stood at ₹450 crore against a full-year revenue of ₹1,290 crore. The company stated these levels are within historical controls. Regarding cash flows, management noted that while FY26 cash flow was negative due to capex on new product streams, operating cash flow is expected to turn positive in FY27 or by Q2FY28 at the latest.
The company also outlined plans to meet the Minimum Public Shareholding (MPS) requirement through a dilution of 4-5%, comprising a 3% Offer for Sale (OFS) where promoters infuse funds back into the company, and a 2% issuance of preference or equity shares.
How might the planned 4-5% equity dilution to meet Minimum Public Shareholding requirements impact existing shareholder value and promoter control in the near term?
What are the specific regulatory or reimbursement hurdles Lords Mark faces in scaling its 50 dialysis centers and integrating AI-powered Renalytics technology into public healthcare systems?
Given the significant margin disparity between MedTech and Renewable Energy, how vulnerable is the consolidated EBITDA target to potential delays in the execution of high-margin MedTech product launches?

































